Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.

摘要: To evaluate whether the addition of an aminoglycoside might enhance clinical efficacy ceftazidime in cystic fibrosis patients with acute exacerbations chronic Pseudomonas lung infections we carried out a prospective, comparative, randomized blind study three schedules: vs. plus sisomicin (C/S) piperacillin sisomicin, for total 60 courses 14 days treatment. Each treatment led to and radiologic improvement marked reduction signs infection. Statistically there was no significant difference responses among schedules. No side effect appeared during treatments or C/S. Hyperpyrexia seen 35% receiving piperacillin. Decrease aeruginosa count less than 10(5) colony-forming units/ml sputum achieved 60% treated C/S 30% who received (statistically not significant). A transient increase mean geometric minimal inhibitory concentrations observed at end combined therapies. larger percentage persistent resistant strains P. after We conclude that as monotherapy may be effective alternative patients. Its seems enhanced by aminoglycoside, although better combination